New answer by Medical Oncologist at Huntsman Cancer Institute at the University of Utah (December 4, 2021)
Yes, I would offer adjuvant endocrine therapy to reduce contralateral breast DCIS recurrence risk, preferably tamoxifen, extrapolating from female breast cancer data.Sharon Gi...